Assessment of somatic mutations in urine and plasma of Wilms tumor patients

Abstract Tumor DNA has been detected in body fluids of cancer patients. Somatic tumor mutations are being used as biomarkers in body fluids to monitor chemotherapy response as a minimally invasive tool. In this study, we evaluated the potential of tracking somatic mutations in free DNA of plasma and urine collected from Wilms tumor (WT) patients for monitoring treatment response. Wilms tumor is a pediatric renal tumor resulting from cell differentiation errors during nephrogenesis. Its mutational repertoire is not completely defined. Thus, for identifying somatic mutations from tumor tissue DNA, we screened matched tumor/leukocyte DNAs using either a panel containing 16 WT‐associated genes or whole‐exome sequencing (WES). The identified somatic tumor mutations were tracked in urine and plasma DNA collected before, during and after treatment. At least one somatic mutation was identified in five out of six WT tissue samples analyzed. Somatic mutations were detected in body fluids before treatment in all five patients (three patients in urine, three in plasma, and one in both body fluids). In all patients, a decrease of the variant allele fraction of somatic mutations was observed in body fluids during neoadjuvant chemotherapy. Interestingly, the persistence of somatic mutations in body fluids was in accordance with clinical parameters. For one patient who progressed to death, it persisted in high levels in serial body fluid samples during treatment. For three patients without disease progression, somatic mutations were not consistently detected in samples throughout monitoring. For one patient with bilateral disease, a somatic mutation was detected at low levels with no support of clinical manifestation. Our results demonstrated the potential of tracking somatic mutations in urine and plasma DNA as a minimally invasive tool for monitoring WT patients. Additional investigation is needed to check the clinical value of insistent somatic mutations in body fluids.

[1]  O. Delattre,et al.  Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis , 2018, International journal of cancer.

[2]  Sanghui Park,et al.  Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder , 2018, Scientific Reports.

[3]  George D. Cresswell,et al.  Somatic TP53 Mutations Are Detectable in Circulating Tumor DNA from Children with Anaplastic Wilms Tumors , 2018, Translational oncology.

[4]  D. Zurakowski,et al.  Causal somatic mutations in urine DNA from persons with the CLOVES subgroup of the PIK3CA‐related overgrowth spectrum , 2018, Clinical genetics.

[5]  L. Biesecker,et al.  Urine cell-free DNA is a biomarker for nephroblastomatosis or Wilms Tumor in PIK3CA-related overgrowth spectrum (PROS) , 2018, Genetics in Medicine.

[6]  K. Birkenkamp-Demtröder,et al.  Re: Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. , 2019, The Journal of urology.

[7]  Qing-Rong Chen,et al.  A Children's Oncology Group and TARGET Initiative Exploring the Genetic Landscape of Wilms Tumor , 2017, Nature Genetics.

[8]  M. Gessler,et al.  TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia , 2017, The journal of pathology. Clinical research.

[9]  Jordan H. Garst,et al.  Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series. , 2017, Lung cancer.

[10]  T. H. van der Kwast,et al.  Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance , 2017, The Journal of urology.

[11]  G. Kaspers,et al.  Wilms Tumor Treatment Outcomes: Perspectives From a Low-Income Setting , 2016, Journal of global oncology.

[12]  M. Scavina,et al.  Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation , 2016, American journal of medical genetics. Part A.

[13]  T. Ørntoft,et al.  Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. , 2016, European urology.

[14]  George D. Cresswell,et al.  Intra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal Evolution and Clinical Implications , 2016, EBioMedicine.

[15]  Fabiana Ramos Vasques,et al.  Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA , 2016, European Journal of Human Genetics.

[16]  Carlos Caldas,et al.  Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer , 2015, Nature Communications.

[17]  P. Laktionov,et al.  Extracellular Nucleic Acids in Urine: Sources, Structure, Diagnostic Potential , 2015, Acta naturae.

[18]  Kathy Pritchard-Jones,et al.  The yin and yang of kidney development and Wilms’ tumors , 2015, Genes & development.

[19]  Eckart Meese,et al.  Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. , 2015, Cancer cell.

[20]  Richard A. Moore,et al.  Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. , 2015, Cancer cell.

[21]  Dinesh Rakheja,et al.  Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours , 2014, Nature Communications.

[22]  M. Berger,et al.  Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  M. Berger,et al.  Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  P. Grundy,et al.  Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour , 2014, Nature Communications.

[25]  G. Getz,et al.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. , 2014, Cancer discovery.

[26]  N. McGranahan,et al.  The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.

[27]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[28]  J. Millholland,et al.  Detection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencing , 2012, Research and reports in urology.

[29]  M. Ychou,et al.  High Fragmentation Characterizes Tumour-Derived Circulating DNA , 2011, PloS one.

[30]  E. Zwarthoff,et al.  Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay. , 2011, The Journal of urology.

[31]  R. Arceci,et al.  Wilms tumor suppressor WTX negatively regulates WNT/β-catenin signaling , 2008 .

[32]  Anne-Claude Gingras,et al.  Wilms Tumor Suppressor WTX Negatively Regulates WNT/ß-Catenin Signaling , 2007, Science.

[33]  O. Landt,et al.  Transrenal DNA as a Diagnostic Tool: Important Technical Notes , 2004, Annals of the New York Academy of Sciences.

[34]  S. Syngal,et al.  Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. , 2004, The Journal of molecular diagnostics : JMD.

[35]  Charles A Powell,et al.  Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. , 2002, The American journal of pathology.

[36]  M. Coppes,et al.  Recent advances in Wilms tumor genetics , 2002, Current opinion in pediatrics.

[37]  M. Stroun,et al.  About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[38]  F. O. Fackelmayer,et al.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.

[39]  C. Amos,et al.  Frequent Association of β-Catenin and WT1 Mutations in Wilms Tumors , 2000 .

[40]  A. Garin,et al.  Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. , 2000, Clinical chemistry.

[41]  C. Amos,et al.  Frequent association of beta-catenin and WT1 mutations in Wilms tumors. , 2000, Cancer research.

[42]  F. Marshall,et al.  Diagnosis of Renal Cancer by Molecular Urinalysis , 1999 .

[43]  M. von Knebel Doeberitz,et al.  Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. , 1999, Cancer research.

[44]  N. Nowak,et al.  Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations , 1994, Nature Genetics.

[45]  D. Housman,et al.  Alternative splicing and genomic structure of the Wilms tumor gene WT1. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Cummings,et al.  The molecular pharmacology of doxorubicin in vivo. , 1991, European journal of cancer.

[47]  J. Verweij,et al.  Mitomycin C. , 1990, Cancer chemotherapy and biological response modifiers.

[48]  H. M. Sobell.  Actinomycin and DNA transcription. , 1985, Proceedings of the National Academy of Sciences of the United States of America.